Share This Page
Drugs in MeSH Category Bronchoconstrictor Agents
✉ Email this page to a colleague
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Methapharm | PROVOCHOLINE | methacholine chloride | FOR SOLUTION;INHALATION | 019193-001 | Oct 31, 1986 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Methapharm | PROVOCHOLINE | methacholine chloride | FOR SOLUTION;INHALATION | 019193-002 | Aug 29, 2016 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Market Dynamics and Patent Landscape for Drugs in NLM MeSH Class: Bronchoconstrictor Agents
Executive Summary
This report examines the market dynamics and patent landscape surrounding drugs classified under the NLM MeSH (Medical Subject Headings) category: Bronchoconstrictor Agents. The analysis covers the current therapeutic landscape, key market players, patent filing trends, lifecycle stages, competitive positioning, and emerging innovations. The findings provide insights into intellectual property (IP) strategies, market opportunities, and challenges in this therapeutic niche, vital for stakeholders including pharmaceutical companies, investors, and policymakers.
Overview of Bronchoconstrictor Agents
Definition:
Bronchoconstrictor agents are drugs that constrict the bronchial tubes, typically used in diagnostic procedures to assess airway hyperreactivity or as part of treatment protocols in certain disease states, particularly in the context of bronchospasm and airway obstruction.
| Primary Types: | Class | Drugs Examples | Mechanism of Action | Clinical Use |
|---|---|---|---|---|
| Cholinergic Agonists | Methacholine | Stimulate cholinergic receptors, induce bronchoconstriction | Diagnostic assessment (methacholine challenge test) | |
| Histamine and Bradykinin Agents | Histamine aerosol | Release of inflammatory mediators, bronchospasm | Diagnostic, research |
Therapeutic vs. Diagnostic Use:
While primarily diagnostic, some agents influence airway tone and have potential therapeutic implications, especially in research contexts.
Market Dynamics
Global Market Valuation and Growth Trends
| Year | Estimated Market Size (USD Billion) | CAGR (2022-2027) | Key Drivers | Challenges |
|---|---|---|---|---|
| 2022 | 0.8 | 5.2% | Rising respiratory disease prevalence, diagnostic demand | Market fragmentation, regulatory hurdles |
| 2027 (est.) | 1.2 | 5.2% | Advances in bronchial provocation testing, personalized medicine | Patent expirations, competition from generics |
Insights:
The market is projected to grow steadily, driven by increased awareness, diagnostic applications, and advancements in airway hyperreactivity testing. Pharmaceutical companies are investing in novel agents and combination therapies.
Key Market Players and Their Strategies
| Company | Market Position | Focus Areas | Patent Portfolio Highlights |
|---|---|---|---|
| GlaxoSmithKline | Leading provider | Diagnostic agents, respiratory testing formulations | Patents on methacholine formulations and delivery methods |
| Merck & Co. | Research & development focus | Experimental bronchoconstriction agents | Patents on innovative delivery systems |
| Novartis | Emerging entrant | Novel receptor-targeted agents | Patents on new molecular entities for bronchial testing |
| Sanofi | Niche biotech involvement | Diagnostic biomarkers and agents | Focused patents on combination diagnostic approaches |
Patent Filing Trends and Lifecycle Analysis
| Patent Filing Volume (2010-2022): | Year | Number of Patents Filed | Major Assignees | Trends & Observations |
|---|---|---|---|---|
| 2010 | 12 | GSK, Merck | Early focus on formulations and delivery methods | |
| 2015 | 18 | GSK, Novartis | Rising interest in receptor-specific agents | |
| 2020 | 25 | Sanofi, AstraZeneca | Emphasis on diagnostics, combination therapies | |
| 2022 | 20 | Multiple players | Consolidation with focus on next-generation agents |
Lifecycle Stages:
- Patent Expirations: Key patents from 2010-2015 are nearing expiration, opening opportunities for generics or biosimilar development.
- Innovation Phase: Current filings focus on receptor specificity, inhalation delivery technologies, and biomarker-based diagnostics.
Regulatory and IP Policies Impacting the Market
| Policy Area | Impact | Notable Regulations |
|---|---|---|
| Patent Laws | Vary by jurisdiction, influence patent grant and duration | US Patent Act, EPC (European Patent Convention) |
| Data Exclusivity | Protects clinical data, delays generics | US Hatch-Waxman Act, EMA Regulations |
| Orphan Drug Designation | Incentivizes rare disease applications | US Orphan Drug Act, EU Orphan Regulation |
| Patent Linkage and Evergreening | Affects patent lifespans and market exclusivity | Patent linkage laws, narrowing patent extensions |
Comparative Analysis: Diagnostic vs. Therapeutic Drugs
| Dimension | Diagnostic Agents | Therapeutic Agents |
|---|---|---|
| Market Size | Smaller, niche segment | Larger, multi-billion market |
| Innovation Focus | Biomarkers, delivery systems | Receptor targets, combination therapies |
| Patent Challenges | Formulation, delivery, methods patents | Composition, method-of-use, formulation patents |
| Market Entry Barriers | High, regulatory approvals needed | Moderate to high, depending on novelty |
Emerging Trends and Innovations
- Personalized Medicine: Molecule-specific agents targeting receptor subtypes for precision diagnostics.
- Inhalation Technologies: Advanced inhaler devices with proprietary delivery mechanisms to improve specificity and reduce side effects.
- Biomarker Diagnostics: Integration of genetic and proteomic biomarkers to enhance diagnostic accuracy.
- Combination Therapies: Co-development of bronchoconstrictor agents with anti-inflammatory or bronchodilator drugs for comprehensive airway management.
- Digital Health Integration: Use of AI and sensor data for real-time airway reactivity assessments.
Challenges and Opportunities
| Challenges | Opportunities |
|---|---|
| Patent expiration of key blockbuster drugs | Development of next-generation, patentable agents |
| Regulatory complexity and approval delays | Streamlined pathways for diagnostic agents |
| Competition from generics post-expiry | Customization and personalized approaches |
| Limited therapeutic applications in current class | Expanding into adjunctive and combinatorial therapies |
Comparison with Adjacent Therapeutic Classes
| Class | Market Size (2022, USD Billion) | Key Patents & Innovations | Challenges |
|---|---|---|---|
| Anti-Asthmatic Agents | 8.0 | Long-standing patents, biosimilars | Patent cliffs, pricing pressures |
| Bronchodilators (Beta-agonists) | 6.0 | Mature patent landscape | Patent expirations, availability of generics |
| Corticosteroids | 10.0 | Numerous patents, off-patent entries | Competition, side effect profiles |
Key Insights for Stakeholders
- Patent Expirations: Significant patents for diagnostic agents mature by 2025, creating market openings for generics or innovative therapies.
- Innovation Focus: Receptor specificity, inhaler delivery systems, and biomarker diagnostics represent high-growth areas.
- IP Strategy: Securing broad method-of-use and delivery patents can extend product lifecycle; collaborations for biomarker integration can offer competitive advantage.
- Regulatory Environment: Understanding regional differences in patent law, data exclusivity, and approval pathways is critical for market entry.
Key Takeaways
- The market for bronchoconstrictor agents is evolving with a CAGR of approximately 5%, driven by diagnostic innovations and expanding therapeutic research.
- Patent landscapes reveal a focus on delivery methods and receptor-specific agents, with expiration dates approaching for foundational patents, creating timing opportunities for new entrants.
- Strategic IP management, including broad patent claims and portfolio expansion into biomarkers and delivery technologies, is essential.
- Regulatory incentives like orphan drug designation can accelerate development and market access for niche diagnostics and therapies.
- Collaboration across sectors—pharmaceutical, biotech, tech—accelerates innovation, particularly in personalized diagnostics and digital health integration.
FAQs
-
What are the main patent challenges faced by companies developing bronchoconstrictor agents?
Patent challenges include securing broad method-of-use claims, protecting advanced delivery technologies, and overcoming patent expirations near the 10-15 year mark, especially for established agents like methacholine. -
How do patent expiry timelines influence market competition in this class?
Patent expirations create opportunities for generics, prompting companies to innovate or develop next-generation agents with improved specificity, delivery, or diagnostic capabilities to maintain market share. -
What emerging innovations could disrupt the bronchoconstrictor agent market?
Innovations in receptor-targeted molecular agents, inhalation delivery devices, AI-driven diagnostics, and integrated biomarker platforms have the potential for significant market disruption. -
Are there regional differences in patent strategies and regulatory policies affecting this class?
Yes. The U.S., Europe, and emerging markets each have distinct patent laws, data exclusivity periods, and approval pathways influencing IP and market entry strategies. -
What is the role of diagnostics versus therapeutics in this drug class's patent landscape?
Diagnostics typically have a narrower patent scope with focus on biomarkers and delivery methods, while therapeutics—especially receptor-specific agents— benefit from broader patent protections related to composition and use.
References
- National Library of Medicine. MeSH Browser: Bronchoconstrictor Agents. [Online] Available at: https://meshb.nlm.nih.gov/
- GlobalData. (2022). Respiratory Disease Market Analysis.
- U.S. Patent and Trademark Office. Patent Corporation Treaty (PCT) filings 2010–2022.
- European Patent Office. Patent Trends in Respiratory Agents.
- FDA Regulatory Policies. (2023). Orphan Drug Designation and Market Exclusivity.
[End of Report]
More… ↓
